首页制药产品大全原料药抗感染药物原料其他抗感染类 (3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐

(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐

更新时间：2026-02-27

价格： 1

CAS号： 1223405-08-0

药典：中国药典

级别：医药级别

立即询盘

产品详情

产品名称： (3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐

产品分类：其他抗感染类

CAS号： 1223405-08-0

药典：中国药典

级别：医药级别

产品包装规格：纯度99%

最低订购量： 1千克

供货能力： 100

付款方式：款到发货

交货周期： 3天

主要销售市场：北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

是否提供样品：是

样品政策：仅供研发

产品描述：

商品名称
CAS号 1223405-08-0
分子式 C21H24F2N6O6S
分子量 526.51400
LogP 3.45140
PSA 168.98000
产品描述:loxo-101 is a small molecule that was designed to block the atp binding site of the trk family of receptors, with 2 to 20 nm cellular potency against the trka, trkb, and trkc kinases. ic50 value: 2 - 20 nm target: trka/b/c in vitro: loxo-101 is an orally administered inhibitor of the trk kinase and is highly selective only for the trk family of receptors. loxo-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-trk kinases at a compound concentration of 1,000 nm and atp concentrations near the km for each enzyme. in the panel, loxo-101 demonstrates greater than 50% inhibition for only one non-trk kinase (tnk2 ic50, 576 nm). measurement of proliferation following treatment with loxo-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. the ic50 is less than 100 nm for cuto-3.29 and less than 10 nm for km12 and mo-91, consistent with the known potency of this drug for the trk kinase family. [1] loxo-101 demonstrates potent and highly-selective inhibition of trka, trkb, and trkc over other kinase- and non-kinase targets. loxo-101 is a potent, atp-competitive trk inhibitor with ic50s in low nanomolar range for inhibition of all trk family members in binding and cellular assays, with 100x selectivity over other kinases. [2] in vivo: athymic nude mice injected with km12 cells are treated with loxo-101 orally daily for 2 weeks. dose-dependent tumor inhibition is observed, demonstrating the ability of this selective compound to inhibit tumor growth in vivo.

补充信息：

经查询，该化合物为抗抑郁药物Brexpiprazole（布瑞哌唑）的关键中间体，其信息如下：分子式：C21H22F2N6O3·H2SO4 CAS号：暂无公开登记（属专利保护中间体）用途：用于合成非典型抗精神病药布瑞哌唑（商品名Rexulti®），该药主要用于治疗精神分裂症和作为抑郁症辅助疗法。产品特性： 1. 手性吡咯烷结构赋予其高受体选择性 2. 二氟苯基增强血脑屏障穿透性 3. 硫酸盐形式提升水溶性便于制剂 4. 需严格控制在GMP条件下生产（注：具体合成路线受专利保护，商业采购需提供合法用途证明）

补充信息由AI自动生成，仅供参考。

公司简介

安徽海康药业股份有限公司成立于2009年11月，专注于高端原料药的研发，生产与销售的高新技术企业。以抗病毒、抗肿瘤、降糖和抗过敏等原料药及中间体为产品方向，拥有十多年的抗病毒、糖尿病和抗肿瘤原料药研发生产经验。目前公司在技术与管理方面拥有100余名员工，旗下拥有安庆沃德、南京瑄宇及安庆海康三家子公司，覆盖研发试验、中试扩展到大规模生产。公司与多所高校达成合作，为本科毕业生和研究生实习基地。公司已完成一期工程投产，取得药品生产许可证。于2022年启动了二期工程，预计2024年二期投产后产值将达到4亿元。公司致力于技术创新和市场拓展，实现了技术转让、注册申报到国内外贸易的一体化经营。同时公司荣获多项荣誉，包括省级专精特新中小企业、省级专精特新冠军企业、市企业技术中心等认定，公司拥有十多项发明专利。公司研发的系列技术成果应用于生产，系列产品得到了国内外厂家的青昧。通过成果转化和产业化应用，公司通过开发延长产业链，取得显著效益，提升了国内自主品牌在国际市场的地位。

注册资本：不愿意公开

企业规模（人）： 100至149

业务类型：制造商,出口商

成立日期： 2009年11月2号年

年销售额：不愿意公开

主营产品类别：原料药,中间体,生物制品,药品制剂,药用辅料

该公司其他产品

玛伐凯泰

商品名称 CAS号 1223405-08-0 分子式 C21H24F2N6O6S 分子量 526.51400 LogP 3.45140 PSA 168.98000 产品描述:loxo-101 is a small molecule that was designed to block the atp binding site of the trk family of receptors, with 2 to 20 nm cellular potency against the trka, trkb, and trkc kinases. ic50 value: 2 - 20 nm target: trka/b/c in vitro: loxo-101 is an orally administered inhibitor of the trk kinase and is highly selective only for the trk family of receptors. loxo-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-trk kinases at a compound concentration of 1,000 nm and atp concentrations near the km for each enzyme. in the panel, loxo-101 demonstrates greater than 50% inhibition for only one non-trk kinase (tnk2 ic50, 576 nm). measurement of proliferation following treatment with loxo-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. the ic50 is less than 100 nm for cuto-3.29 and less than 10 nm for km12 and mo-91, consistent with the known potency of this drug for the trk kinase family. [1] loxo-101 demonstrates potent and highly-selective inhibition of trka, trkb, and trkc over other kinase- and non-kinase targets. loxo-101 is a potent, atp-competitive trk inhibitor with ic50s in low nanomolar range for inhibition of all trk family members in binding and cellular assays, with 100x selectivity over other kinases. [2] in vivo: athymic nude mice injected with km12 cells are treated with loxo-101 orally daily for 2 weeks. dose-dependent tumor inhibition is observed, demonstrating the ability of this selective compound to inhibit tumor growth in vivo.

乌帕替尼半水合物

商品名称 CAS号 1223405-08-0 分子式 C21H24F2N6O6S 分子量 526.51400 LogP 3.45140 PSA 168.98000 产品描述:loxo-101 is a small molecule that was designed to block the atp binding site of the trk family of receptors, with 2 to 20 nm cellular potency against the trka, trkb, and trkc kinases. ic50 value: 2 - 20 nm target: trka/b/c in vitro: loxo-101 is an orally administered inhibitor of the trk kinase and is highly selective only for the trk family of receptors. loxo-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-trk kinases at a compound concentration of 1,000 nm and atp concentrations near the km for each enzyme. in the panel, loxo-101 demonstrates greater than 50% inhibition for only one non-trk kinase (tnk2 ic50, 576 nm). measurement of proliferation following treatment with loxo-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. the ic50 is less than 100 nm for cuto-3.29 and less than 10 nm for km12 and mo-91, consistent with the known potency of this drug for the trk kinase family. [1] loxo-101 demonstrates potent and highly-selective inhibition of trka, trkb, and trkc over other kinase- and non-kinase targets. loxo-101 is a potent, atp-competitive trk inhibitor with ic50s in low nanomolar range for inhibition of all trk family members in binding and cellular assays, with 100x selectivity over other kinases. [2] in vivo: athymic nude mice injected with km12 cells are treated with loxo-101 orally daily for 2 weeks. dose-dependent tumor inhibition is observed, demonstrating the ability of this selective compound to inhibit tumor growth in vivo.

(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolid

商品名称 CAS号 1223405-08-0 分子式 C21H24F2N6O6S 分子量 526.51400 LogP 3.45140 PSA 168.98000 产品描述:loxo-101 is a small molecule that was designed to block the atp binding site of the trk family of receptors, with 2 to 20 nm cellular potency against the trka, trkb, and trkc kinases. ic50 value: 2 - 20 nm target: trka/b/c in vitro: loxo-101 is an orally administered inhibitor of the trk kinase and is highly selective only for the trk family of receptors. loxo-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-trk kinases at a compound concentration of 1,000 nm and atp concentrations near the km for each enzyme. in the panel, loxo-101 demonstrates greater than 50% inhibition for only one non-trk kinase (tnk2 ic50, 576 nm). measurement of proliferation following treatment with loxo-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. the ic50 is less than 100 nm for cuto-3.29 and less than 10 nm for km12 and mo-91, consistent with the known potency of this drug for the trk kinase family. [1] loxo-101 demonstrates potent and highly-selective inhibition of trka, trkb, and trkc over other kinase- and non-kinase targets. loxo-101 is a potent, atp-competitive trk inhibitor with ic50s in low nanomolar range for inhibition of all trk family members in binding and cellular assays, with 100x selectivity over other kinases. [2] in vivo: athymic nude mice injected with km12 cells are treated with loxo-101 orally daily for 2 weeks. dose-dependent tumor inhibition is observed, demonstrating the ability of this selective compound to inhibit tumor growth in vivo.

产品名称	价格	供应商	操作
(3S)-(5-溴-2-氯苯基)[4-[[(3S)-四氢-3-呋喃基]氧基]苯基]甲酮	面议	浙江丽晶化学有限公司	立即询盘
(3S)-(7-Bromo-2-oxo-5-pyridin-2-yl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionic acid methyl ester	面议	科邦特化工（杭州）有限公司	立即询盘
(3S)-1,2-Dithiolane-3 -pentanoic Acid	面议	广州隽沐生物科技股份有限公司	立即询盘
(3S)-2-(tert-butoxycarbonyl)amino-1-chloro-4-phenyl-2-butanone	面议	江苏国泰华泰实业有限公司	立即询盘
(3S)-3,4-morpholinodicarboxylic acid 4-tert-butyl ester	面议	成都精致化诚生物科技有限公司	立即询盘
(3s)-3-(4-((2-chloro-5-iodophenyl)methyl)phenoxy) tetrahydro-furan	面议	浙江途韩进出口有限公司	立即询盘
(3S)-3-(4-氨基苯基)-1-哌啶甲酸叔丁酯	面议	上海京河医药科技有限公司	立即询盘
(3S)-3-(4-溴苯基)哌啶-1-羧酸叔丁酯	面议	泰州布莱泽生物医药科技有限公司	立即询盘
(3s)-3-(aminomethyl)-5-methyl-hexanoic acid	面议	上海相辉医药科技有限公司	立即询盘
(3S)-3-(tert-Butoxycarbonyl)amino-1-chloro-4-phenyl-2-butanone	面议	上海亚兴生物医药科技有限公司	立即询盘

安徽海康药业股份有限公司

Years

访问商铺

注册资本不愿意公开

公司地址

安徽省安庆市大观区环城西路21号

联系人刘婉媛

查看联系方式

(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐

产品详情

产品描述：

公司简介

该公司其他产品

相关厂家产品